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Introduction
Many modern radiotherapy techniques have been 
developed in recent decades in response to the need 
to increase the radiation dose to the tumour, while 
delivering the radiation therapy as accurately as 
possible. Such advanced techniques include inten-
sity modulated radiotherapy (IMRT), volumetric 
modulated arc therapy (VMAT), stereotactic body 
radiation therapy (SBRT), and tomotherapy (TT), 
among others. 
While it is accepted that these treatments deliver 
more accurate radiation, there are concerns regard-
ing the doses delivered to the nearby organs at risk 
(OARs). Moreover, the high energy levels used in 
these treatments may result in signifi cant scatter 
irradiation. For this reason, it is essential to measure 
and calculate these low doses; however, doing so 
presents many challenges [1–4], primarily because 
the treatment planning systems (TPS) do not cal-
culate doses outside the planning target volume 
(PTV) more than a few centimetres from the edge 
of the radiation fi eld. According to the International 
Commission on Radiological Protection (ICRP), it 
is necessary to estimate doses outside the PTV from 
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Abstract. Introduction. The rapid development of new radiotherapy technologies, such as intensity modulated 
radiotherapy (IMRT) or tomotherapy, has resulted in the capacity to deliver a more homogenous dose in the 
target. However, the higher doses associated with these techniques are a reason for concern because they may 
increase the dose outside the target. In the present study, we compared 3DCRT, IMRT and tomotherapy to as-
sess the doses to organs at risk (OARs) resulting from photon beam irradiation and scattered neutrons. Material 
and methods. The doses to OARs outside the target were measured in an anthropomorphic Alderson phantom 
using thermoluminescence detectors (TLD 100) 6Li (7.5%) and 7Li (92.5%). The neutron fl uence rate [cm–2·s–1] 
at chosen points inside the phantom was measured with gold foils (0.5 cm diameter, mean surface density 
of 0.108 g/cm3). Results. The doses [Gy] delivered to the OARs for 3DCRT, IMRT and tomotherapy respec-
tively, were as follows: thyroid gland (0.62 ± 0.001 vs. 2.88 ± 0.004 vs. 0.58 ± 0.003); lung (0.99 ± 0.003 vs. 
4.78 ± 0.006 vs. 0.67 ± 0.003); bladder (80.61 ± 0.054 vs. 53.75 ± 0.070 vs. 34.71 ± 0.059); and testes 
(4.38 ± 0.017 vs. 6.48 ± 0.013 vs. 4.39 ± 0.020). The neutron dose from 20 MV X-ray beam accounted for 0.5% 
of the therapeutic dose prescribed in the PTV. The further from the fi eld edge the higher the contribution of this 
secondary radiation dose (from 8% to ~45%). Conclusion. For tomotherapy, all OARs outside the therapeutic 
fi eld are well-spared. In contrast, IMRT achieved better sparing than 3DCRT only in the bladder. The photoneu-
tron dose from the use of high-energy X-ray beam constituted a notable portion (0.5%) of the therapeutic dose 
prescribed to the PTV. 
Keywords: 3DCRT • IMRT • low doses • neutron doses • thermoluminescent detectors (TLD) • tomotherapy 
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all sources in order to assess total stochastic risks, 
and thus adequately justify radiation exposure in 
patients treated with radiotherapy (RT) [5]. 
Numerous studies have evaluated the radiation 
doses in a body during IMRT and the conventional 
three-dimensional conformal radiotherapy (3DCRT) 
[6–10], although fewer have done so for tomotherapy. 
We carried out the present study in which we com-
pared 3DCRT, IMRT and tomotherapy to assess the 
doses received by the organs at risk (OARs) resulting 
from photon beam irradiation and scattered neutrons. 
The study was performed in an anthropomorphic 
phantom in a prostate cancer model, with dose mea-
sured with lithium fl uoride chips (TLD 100). 
Material and methods 
Treatment plan preparation 
For measurements of low doses in the body, an 
anthropomorphic phantom with special thermolu-
minescent dosimeter (TLD) inserts were prepared. 
The thickness of each layer in the Alderson phantom 
is 2.5 cm and the distance between the dosimetric 
points is 3 cm, thus allowing for an accurate deter-
mination of doses in the selected organs. The doses 
in OARs located outside the target were measured in 
the anthropomorphic Alderson phantom using ther-
moluminescence detectors (TLD) 100 (6Li (7.5%) 
and 7Li (92.5%)); (Harshaw Chemical Company). 
In the fi rst phase, the computed tomography 
(CT) scans were acquired. Subsequently, the clini-
cal target volumes (CTV) were contoured for the 
prostate (CTV1), lymph nodes (CTV2) and OARs 
(bladder, rectum, lung, thyroid and testes). The tar-
get consisted of the whole pelvic lymph nodes and 
the prostate gland with seminal vesicles. 
In the next stage, three treatment plans were cal-
culated for each of the techniques: 3DCRT (20 MV), 
IMRT (20 MV) and tomotherapy (6 MV). The dose 
prescription for each technique was 2 Gy per fraction 
up to the total dose of 76 Gy. These energies were used 
according to the standard protocol for patients with 
prostate cancer at our institution. For organs inside 
or close to the treatment fi elds (rectum, bladder, tes-
tes), the doses were read from the TPS. However, the 
readout of doses for thyroid and lung from the TPS 
was not possible because commercial systems do not 
calculate doses at such long distances outside of the 
target volume. 
The aim of each treatment plan was to provide 
therapeutic dose of 2 Gy using three different tech-
niques, with maximum protection of organs at risk. 
All parameters of the treatment plans were applied 
according to the protocol used in our institute for 
patients with prostate cancer. The treatment plans 
for 3DCRT technique consisted of four beams – box 
technique (0, 90, 180 and 270). The total number of 
Monitor Units (MU) was 163 per fraction. For IMRT, 
the dose distribution was prepared using seven 
coplanar beams with the fi eld geometry of 0°, 50°, 
105°, 145°, 215°, 255° and 300°. The total number 
of MUs was 779 per fraction. The tomotherapy plan 
was generated with the Hi-Art Treatment Planning 
System (version 4.0.4.17). Based on results from 
the Skórska et al. [11] study, we used the treatment 
planning parameters presented in Table 1. The actual 
modulation factor was 1.95. The dose was calculated 
using a superposition/convolution algorithm with a 
fi ne dose calculation grid (0.254 cm × 0.254 mm × 
0.3 cm). The plan was optimized to reduce the dose 
to the OARs to a minimum, while the dose to the 
PTV was maintained in accordance with the ICRU 
83 Report [12]. The irradiation time was 407.5 s 
and the expected number of MUs was 5863 [13]. 
Figures 1 and 2 show the dose distribution in the 
phantom for plans 3DCRT, IMRT and tomotherapy. 
Dose measurements 
A total of 100 TLDs per treatment modality were 
calibrated at 1 Gy. Of these, 73 were chosen for 
measurements, with a calibration factor below 3%. 
This means that the difference between different cali-
bration measurements was not more than 3% [14]. 
Table 1. The parameters for the tomotherapy plan 
Field width 2.5 cm
Pitch 0.287
Planning modulation 
   factor 2.700
Plan calculation grid FINE (0.254 cm × 0.254 mm)
Fig. 1. 3DCRT (a) and IMRT (b) plan for anthropomorphic phantom for prostate gland and lymph nodes. 
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Neutron measurements 
Neutron fl uence rate [cm–2·s–1] at chosen points 
inside the Rando® phantom was measured in terms 
of neutron activation analysis (NAA) with the use 
of gold foils in the shape of discs that were 0.5 cm 
in diameter and having a mean surface density of 
0.108 g/cm3. The induced activity of 198Au, measured 
with the semiconductor gamma spectrometer in 
terms of net area under the peak 411 keV, was di-
rectly used to obtain the slow neutron fl uence rate 
values. On the basis of an additional (without an 
anthropomorphic phantom) measurement of ther-
mal neutron fl uence rate th in the linac isocenter, 
the quantity of neutron source strength Q [s–1] was 
estimated using relation (1). Subsequently, the fast 
component, which contains direct and scattered 
fractions of neutron flux, was calculated using 
Eq. (2) at a distance of r [cm] from the beam axis, 
where OARs were located with respect to the thera-
peutic plan isocenter and for the surface S [cm2] of 
the room walls of the linac bunker. 
(1) 
(2) 
Neutron dose equivalent at each measuring point 
(the same as for photon dose measurements) was 
determined using fl uence-to-dose conversion coef-
fi cients (CF–D). These were calculated from Eq. (3) 
involving the average neutron energy (Eavg), adopted 
from AAPM Report 19 [15], separately for slow 
and fast components of neutron fl ux. Based on the 
analysis of neutron spectra given in the literature, 
[16–18] the average neutron energy were taken as 
0.2 eV and 0.5 MeV for slow and fast components, 
respectively. All quantities connected with neutron 
radiation were referred to the therapeutic dose of 
1 Gy deposited in the target volume [19–23]. 
(3) 
Results 
Mean dose to the bladder using TPS 
The bladder is the organ located closest to the PTV, 
and therefore, it is possible to measure the dose using 
the TPS. Notable differences among the three RT 
techniques were observed for the bladder volume 
included in the therapeutic fi eld. Use of the 3DCRT 
technique resulted in larger doses to the bladder vs. 
IMRT, as shown in Table 2, which shows the mean 
dose to the various bladder regions for 3DCRT, 
IMRT and tomotherapy (TT). 
Dose measurements 
Table 3 shows the comparison of out-of-fi eld doses 
between 3DCRT, IMRT and tomotherapy. As shown 
in Table 3, the scattered radiation from the patient 
predominates in the region near the therapeutic 
fi eld. However, as the distance from the fi eld edge in-
creases, the radiation scattered by the collimator, the 
transmission through the collimator and machine 
leakage becomes more predominant [24]. A higher 
beam energy leads to an increase in the out-of-fi eld 
dose. The effect is enhanced in the proximity of the 
2 1
fast 2
5.4cm s
4
Q Q
r S
       Fig. 2. Tomotherapy plans for anthropomorphic phantom. 
Table 2. Mean doses calculated in TPS for the bladder for 3DCRT, IMRT and TT techniques per 1 fraction 
Part of the bladder
3DCRT IMRT TT
Mean dose [Gy] Mean dose [Gy] Mean dose [Gy]
Top 2.024 1.061 0.970
Front wall 2.016 1.107 0.941
Back wall 2.006 1.311 1.060
Centre 2.000 1.250 0.995
Down 1.990 1.404 1.103
Mean dose 2.004 1.245 1.029
Table 3. The results of measurements of out-of-fi eld irradiation for 3DCRT, IMRT and TT 
Localization
IMRT 3DCRT TT
Mean dose [Gy] Mean dose [Gy] Mean dose [Gy] 
Thyroid   2.88 ± 0.004   0.62 ± 0.001   0.58 ± 0.003
Lungs   4.76 ± 0.006   0.99 ± 0.003   0.67 ± 0.003 
Bladder 53.75 ± 0.070 80.60 ± 0.054 34.71 ± 0.059
Testes   6.48 ± 0.013   4.37 ± 0.017   4.38 ± 0.020
1.26 thQ
S

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4.4 10 n / cm
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fi eld edge, where the dose drop is much sharper for 
6 MV photons than for 15 and 20 MV photons. 
3DCRT 
For 3DCRT, the bladder was located within the 
radiation fi eld, and therefore, received a dose that 
was nearly equal to the dose to the prostate. The 
dose in the thyroid, located approximately 60 cm 
from the central beam axis (CAX), was 0.621 Gy, 
which is about 1% of the CAX. The dose in the lung 
equalled 1.3% of the total dose. In the phantom, the 
TLDs were located on the surface of lungs, both at 
peripheral and central parts. The detectors located 
near the pelvis yielded higher dose measurements 
than TLDs located in other areas. The mean dose 
to the bladder with 3DCRT was 80.6 Gy. The testes 
were located close to the radiation fi eld and received 
4.4% of the total dose. 
IMRT 
For IMRT, the bladder was located partially in the 
fi eld, and received a dose similar to that received by 
the prostate. The radiation fi eld was larger than in 
3DCRT, and consequently the dose to some OARs 
was higher; however, the dose to the bladder was 
lower than with 3DCRT (53.7 Gy vs. 80.6 Gy) 
because it was outside the fi eld of radiation. The 
total IMRT dose to the thyroid gland was approxi-
mately 5 times higher than with 3DCRT (2.88 Gy vs. 
0.62 Gy), representing about 4% of the dose in the 
PTV. In the lungs, the measured dose was 4.8 Gy. 
The dose in the testes was 2 Gy larger than that 
achieved with 3DCRT. 
Tomotherapy 
For tomotherapy, the total doses (for complete treat-
ment process to 76 Gy) to the thyroid gland, lungs, 
bladder, and testes were, respectively, 0.6, 0.7, 34.7 
and 4.4 Gy. 
Neutron dose results 
The neutron effective dose (Table 4) did not vary 
signifi cantly across the whole body of the phantom 
for IMRT technique1: the arithmetic mean over the 
complete results of photoneutron dose estimation is 
5.777 mSv/Gy and the standard deviation of this mean 
value is 0.127. The dispersion of the results achieved 
at particular points across the phantom reaches only 
19%. However, the dose tended to decrease as the 
distance from the central beam axis (CAX) increased, 
a phenomenon that is explained by the thermalization 
of neutrons and subsequent capture. The symmetrical 
(with respect to the long axis of the phantom/thera-
peutic couch) distribution of neutron fl uence can be 
observed in Fig. 3. This distribution is connected 
with the specifi c treatment plan for IMRT technique 
implemented in the present research. The uncertainty 
of these values (given in Table 4) are high because they 
are affected by several factors, the most important of 
which is related to the net peak area dependent on 
the spectrometer counting statistics (when the activity 
of detection foil is assigned), and the fl uence-to-dose 
conversion coeffi cients used (10%). 
Discussion 
Modern radiotherapy systems deliver highly targeted 
doses. However, because TPS do not calculate doses 
more than few centimetres outside the PTV, organs 
outside the fi eld may receive high doses, leading to 
a multitude of adverse effects. In the present study, 
we evaluated three common RT modalities – IMRT, 
SBRT and tomotherapy – in a phantom model to 
determine the doses from both scattered and direct 
radiation delivered to the surrounding OARs. The 
main finding was that tomotherapy provided 
the best overall sparing of organs located outside 
the therapeutic fi eld. Surprisingly, 3DCRT achieved 
better sparing than IMRT for all organs except for 
bladder. In addition, the photoneutron dose (re-
Table 4. The effective estimated out-of-fi eld neutron dose for prostate IMRT 
Localization
Effective dose [mSv/Gy] Total neutron effective 
dose normalized 
to 76 Gy in PC [mSv]
Mean normalized 
dose in organ
[mSv] Slow neutrons Fast neutrons
Pelvis – right side 0.022 ± 0.008 6.4 ± 2.7 6.4 ± 2.8
6.201
Pelvis – left side 0.038 ± 0.009 6.0 ± 1.8 6.0 ± 1.8
Right lung – corner 0.032 ± 0.010 5.9 ± 2.3 6.0 ± 2.3
5.832
Left lung – corner 0.026 ± 0.012 6.1 ± 3.2 6.1 ± 3.2
Right lung – centre 0.026 ± 0.016 5.9 ± 4.2 6.0 ± 4.2
Left lung – centre 0.050 ± 0.014 5.3 ± 1.9 5.4 ± 1.9
Right lung – top 0.017 ± 0.008 5.9 ± 3.1 5.9 ± 3.1
Left lung – top 0.023 ± 0.010 5.7 ± 3.0 5.7 ± 3.0
Right eye 0.024 ± 0.009 5.161 ± 2.407 5.184 ± 2.418
5.189
Left eye 0.023 ± 0.010 5.170 ± 2.540 5.194 ± 2.552
1Doses for neutrons were measured in cooperation with 
another institute. Doses were measured only for IMRT 
technique, and unfortunately it was not possible to make the 
measurements for the other two techniques.
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sulting from the use of high-energy X-ray beam) 
constituted approximately 0.5% of the therapeutic 
dose prescribed in the PTV. 
As expected, doses to the remaining points were 
higher for IMRT, but the magnitude of doses at the 
more distant points became quite small. The differ-
ences can be explained by considering the different 
components of the peripheral dose: (1) the linear 
accelerator head leakage, which affects the entire 
body equally and is directly proportional to moni-
tor units, (2) the internal scatter, which primarily 
affects tissues several centimetres from the beam 
edge and is directly proportional to fi eld size, and 
(3) the entrance and exit extra-target doses in the 
plane of beams will expose more tissues to lower 
doses in the plane of the beams. 
Measuring low doses presents many challenges 
because the spectrum of the scatter radiation is 
unknown, and detectors must therefore be inde-
pendent of the energy spectrum. Moreover, it is not 
possible to verify doses in OARs located outside the 
therapeutic fi eld in vivo. For this reason, anthropo-
morphic phantoms such as the Alderson phantom 
with special TLD inserts are needed. This phantom 
provides the ideal conditions for dose verifi cation 
outside the target, and the TLDs are both precise 
and independent of the energy spectrum. 
As discussed previously, the lack of information 
from TPS regarding doses outside the beam path is 
problematic. Similarly, the fact that the TPS does 
not account for neutron radiation, which in modern 
RT techniques can constitute a signifi cant part of 
the dose to organs outside the target, presents an 
additional problem. It is clear that when high-energy 
X-ray beams are used in radiotherapy treatment, 
the presence of secondary neutron radiation should 
also be taken into account. Computer simulations 
of the spectra of therapeutic photon beams [25, 26] 
have shown that up to 30% of photons could have 
energy above the threshold of nuclear reactions (, 
n) for heavy elements constituting the accelera-
tor head. These photonuclear interactions are the 
main source of fast neutrons, produced mostly via 
giant dipole resonance (GDR) [27]. As the photo-
neutrons leave the linear accelerator (linac), their 
energy spectrum becomes moderated. Therefore, 
in the isocenter, two main components are distin-
guished: the fast one with an average energy of about 
0.5 MeV, and the slow one with the distribution 
peaked at thermal energy (EAv = 0.025 eV) and a 
tail on the high-energy site (EAv = 0.05 MeV), as 
several studies have shown [28, 29]. Since the linear 
energy transfer (LET) and the relative biological ef-
fectiveness (RBE) of neutrons depend strongly on 
their energy, these two main components should be 
taken into account when evaluating the additional 
dose from secondary radiation during radiotherapy. 
A somewhat surprising fi nding of this study was 
that IMRT resulted in worse OAR sparing than 
3DCRT. The reasons for this difference may be ex-
plained by the longer beam-on time required with 
IMRT, and the consequent increased exposure to 
leakage radiation. Moreover, the use of more than 
four fi elds resulted in a larger volume of tissue ex-
posed to relatively low doses [30, 31]. As compared 
to the conventional 3DCRT, IMRT requires the emis-
sion of more MUs to deliver the same dose to PTV. 
Also, the fi eld size does not remain constant during 
the whole procedure. These two factors greatly in-
fl uence the production of photoneutrons, as well as 
the contribution of fast neutrons (of higher RBE), 
which is connected with the fi eld size. The effective 
neutron dose relates also to the depth inside the 
body (phantom). Multi-directional dose delivery 
in the IMRT technique causes the geometry of 
neutron irradiation to be more isotropic. To avoid 
neutron irradiation of asymmetrical OARs, changes 
in the treatment plan, such as the use of a different 
distribution of beam directions (i.e., not symmetri-
cal), could be considered. 
The bladder and testes, as accepted, received 
the highest dose because the OAR in 3DCRT was 
within the fi eld of radiation and very near the fi eld 
of radiation for IMRT and tomotherapy. In addition, 
neutron contamination from high-energy therapeutic 
beams (such as, the 20 MV IMRT beam) undoubt-
edly contributed to these doses. In other regions 
(pelvis, chest and eyes), the effective doses due 
to photoneutrons were estimated with the NAA 
method. 
Limitations 
The doses in OARs were measured under ideal 
conditions: there was no movement of the phantom 
Fig. 3. The distribution of neutron fl uence during prostate IMRT normalized to 1 Gy of dose in PTV (a) and of the 
anthropomorphic phantom (b). The slow (black) and the fast (grey) components are separated, showing the decrease 
of total neutron fl uence when the distance from the isocentre is increased. 
a b
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during the treatment. In case of a real patient, these 
doses would be more variable depending on the organ 
motion or bladder and rectal fi lling. In the phantom, 
the dose measurements were clustered around the 
same range of values due to the stable nature of 
phantom geometry; in a live patient, this would not 
be the case, but for the organs placed at a distance 
of 50–60 cm from the isocenter, the movements can 
be insignifi cant. 
Conclusion 
Among the three treatment modalities evaluated in 
the present study, we found that tomotherapy pro-
vides the best OAR sparing. Surprisingly, 3DCRT 
provided better sparing than IMRT for all OARs 
except the bladder. The further from the fi eld edge 
the higher the contribution of this secondary radia-
tion dose. The use of lower energies, when feasible, 
allows avoiding undesirable scatter radiation and 
its negative effects. 
The low doses and secondary radiation can 
have an impact on the normal tissues and OARs, 
therefore, more research in this area is needed. Re-
search also requires relation doses in organ at risk to 
stochastic effects, which are the subject of another 
work of the authors. 
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